Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Psoriasis Treatment Market size is anticipated to increase from USD 30.67 million in 2024 to USD 90.72 million by 2037, exhibiting a CAGR of around 8.7% during the forecast period, between 2025 and 2037. Currently in 2025, the industry revenue of psoriasis treatment is estimated at USD 32.54 million.
Psoriasis is sometimes considered as a genetic disease that is triggered by surrounding environment. Symptoms often get worse during winter, and infections and psychological stress play a major role in these symptoms. As per the statistics by the World Health Organization (WHO), psoriasis is a serious global problem, with over 100 million individuals affected worldwide at any point of time. Hence, the need for psoriasis treatment has risen owing to the disease's continually expanding patient population. As a result, the market for psoriasis drugs is seeing a significant increase in both demand and supply.
Further, owing to the growing prevalence of psoriasis, the government are increasing its initiatives in order spread awareness regarding psoriasis. Hence, this factor is estimated to boost the demand for psoriasis treatment among people. Also, the market has been greatly boosted by the growing amount of research and development being done in the field of therapeutics by the major market participants. The amount of adverse effects that patients experience after receiving contemporary medicine therapy has decreased as a result of the developments made by the major psoriasis treatment market competitors. Additionally, it has been estimated that the prevalence of psoriasis is higher in the geriatric population. However, it has also been observed that regularity is also growing among young people all around the globe. Therefore, owing to this factor the demand is estimated to rise for the treatment.
Psoriasis Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Growing Geriatric Population – According to the World Health Organization, the number of persons in the globe who are 60 years or older would double (2.1 billion) by 2050. Between 2020 and 2050, the number of people 80 or older is projected to treble, reaching 426 million. The huge senior population has demonstrated to be helpful for market expansion owing to the high frequency of skin disorders among this cohort. Approximately 14% of elderly psoriasis patients have moderate-to-severe disease, necessitating systemic therapies. Hence this factor is estimated to boost the growth of the psoriasis treatment market
- Increasing Prevalence of Psoriasis across the Globe – Psoriasis is an autoimmune inflammatory disorder resulting in overproduction of skin cells, leading to an itchy and painful skin condition. According to the National Psoriasis Foundation (NPF), globally around 125 million patients were suffering from psoriasis in 2020.
- Higher Demand for Psoriasis Treatment Amid Pandemic – According to the data published by Frontiers in Medicine, it was reported that in the US, Spain, and South Korea, around 3.5% to 32.5% of patients diagnosed with Covid-19 were suffering from psoriasis. The impact of COVID-19 resulted in a considerably higher growth in 2020.
- Increasing Awareness Regarding Psoriasis Treatment – People are becoming more aware about the heredity of psoriasis. About 1 out of 3 people with psoriasis have a relative with psoriasis. Moreover, if one parent has psoriasis, a child has about a 10% chance of having psoriasis, while if both parents have psoriasis, a child has a 50% chance of developing the disease.
- Increased Research and Development for Enhancement of Treatment – Increase in research and development, advancement of treatment, surge in healthcare expenditure, and increase in psoriasis research and pipeline drugs positively affects the psoriasis treatment market. According to the data by the World Bank, 2.63% of the GDP was spend for R&D activities in 2020.
Challenges
- High Cost of Medicine – Psoriasis is a chronic condition that could be very expensive. According to National Psoriasis Federation (NPF), it was estimated that one in three people with the condition have trouble paying for the cost of treatment, and a tube of topical medication costs between USD 500 to USD 600. Therefore, despite the disease's expanding prevalence, the market expansion over the projection period would likely be constrained by high treatment pharmaceutical costs and unfavorable reimbursement regulations in emerging nations.
- Variation in Effectiveness of Different Medications
- Lack of Proper Reimbursement Policies
Psoriasis Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.7% |
|
Base Year Market Size (2024) |
USD 30.67 million |
|
Forecast Year Market Size (2037) |
USD 90.72 million |
|
Regional Scope |
|
Psoriasis Treatment Segmentation
Type (Plaque Psoriasis, Psoriatic Arthritis)
The global psoriasis treatment market is segmented and analyzed for demand and supply by type into plaque psoriasis, psoriatic arthritis and others. Out of which the plaque segment is anticipated garner the largest revenue by the end of 2037. The growth of this segment can be attributed to growing prevalence of plaque psoriasis among population. For instance, the most typical form of psoriasis is plaque. Approximately 5 million adults are impacted. Plaque psoriasis affects between 70% and about 80% of psoriasis sufferers. Hence the demand for psoriasis treatment is estimated to increase. Psoriasis vulgaris, also known as plaque psoriasis, is a persistent (chronic) autoimmune condition that accelerates cell division. Further, plaque psoriasis could cause itchiness and large amount of pain, which may give burning or sting sensation. Hence, treating plaque psoriasis is necessary. Therefore, systematic drugs are usually employed to the patient suffering with the same. These systematic drugs are known for regulating immune system and is also estimated to reduce the prevalence of cell growth.
Route of Administration (Oral, Parenteral/systematic, Topical)
The global psoriasis treatment market is also segmented and analyzed for demand and supply by route of administration into oral, parenteral/systematic and topical segment. Amongst these segments, the parenteral/systematic segment is anticipated to hold the largest market share by the end of 2037, owing to its high convenience. Large number of people estimated it to be one of the easiest application method as compared to other methods. Usually parenteral/systematic treatment is recommended only if the patients has moderate or severe psoriasis. Less than 4% of the body is affected by mild psoriasis; about 4% to 10% is termed moderate; and more than 9% is considered severe. Hence, as it affects huge part of body the importance of treatment has grown over the years.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Class |
|
|
By Type |
|
|
By Route of Administration |
|
|
By Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportPsoriasis Treatment Industry - Regional Synopsis
North American Market Forecast
The North American psoriasis treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2037. A strong presence of well- equipped infrastructure and rising long-term investment and advanced healthcare facilities is most likely to boost the market in the region. As per the data by the World Bank, 16.32% of the GDP was spent on healthcare services in the North America region in 2019. Further, the growing prevalence of skin disorders among people is also estimated to boost the growth of the market. In addition, people are increasing using topical pain relief ways in the form of creams and gels for the treatment of psoriasis, that is further expected to boost the market’s growth in the region. Additionally, rising initiatives in order to make people aware about the growing prevalence of psoriasis are also estimated to drive the market for psoriasis treatment. For instance, in the United States, August is recognized as "National Psoriasis Awareness Month" every year with the goal of raising awareness of the condition. The NPF-sponsored campaign presents a special chance to inform the public and dispel common misconceptions about the illness. It serves as a platform for patient education on a variety of subjects, including management of the inflammatory and frequently irritable condition, treatment, causes, and triggers.
Companies Dominating the Psoriasis Treatment Landscape
- LEO Pharma A/S
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Amgen Inc.
- UCB S.A.
- Merck & co. Inc.
- Evelo Biosciences Inc.
- Sun Pharmaceutical Industries ltd.
- Johnson & Johnson Services Inc.
- Navartis AG
- AbbVie Inc.
- Pfizer Inc.
In the News
-
LEO Pharma – LEO Pharma receives positive CHMP opinion of adtralza for the treatment of adolescents with moderate-to-severe atopic dermatitis.
-
Amgen Inc. – Amgen announces positive top-line results from otzela phase 3 discreet study in moderate to severe genital psoriasis
Author Credits: Radhika Pawar
- Report ID: 4625
- Published Date: Mar 21, 2025
- Report Format: PDF, PPT
